表紙:呼吸器診断の世界市場
市場調査レポート
商品コード
908888

呼吸器診断の世界市場

Respiratory Diagnostics

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 286 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

呼吸器診断の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 286 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の呼吸器診断市場を調査し、市場の概要、最終用途(病院/臨床検査室、診療所、基準試験所、その他)、疾患(結核、喘息、慢性閉塞兵肺疾患、その他)、地域別の市場シェア、需要動向、売上額の推移と予測、市場の成長要因、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 注目企業
  • 市場動向と成長要因
  • 世界市場の見通し

第3章 市場分析

  • 地域市場の分析
  • 米国
    • 市場概要
    • 市場シェア:企業別
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の欧州諸国
  • アジア太平洋地域
  • オーストラリア
  • インド
  • 韓国
  • その他のアジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ地域
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他の中東地域
  • アフリカ

第4章 競合情勢

  • ABBOTT LABORATORIES
  • ALERE
  • BIO-RAD LABORATORIES
  • COSMED SRL
  • PHILIPS HEALTHCARE
  • SDI DIAGNOSTICS
  • SEEGENE
  • THERMO FISHER SCIENTIFIC
  • BIOMERIEUX SA

第5章 調査資料

目次
Product Code: MCP14425

Abstract:

Global Respiratory Diagnostics Market to Reach $9.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Respiratory Diagnostics estimated at US$6.3 Billion in the year 2020, is projected to reach a revised size of US$9.5 Billion by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027. Tuberculosis, one of the segments analyzed in the report, is projected to record a 5.9% CAGR and reach US$3.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Asthma segment is readjusted to a revised 6.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.7 Billion, While China is Forecast to Grow at 9.3% CAGR

The Respiratory Diagnostics market in the U.S. is estimated at US$1.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 9.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 5.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Chronic Obstructive Pulmonary Disease Segment to Record 6.9% CAGR

In the global Chronic Obstructive Pulmonary Disease segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$949.1 Million in the year 2020 will reach a projected size of US$1.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027, while Latin America will expand at a 8.2% CAGR through the analysis period.

Select Competitors (Total 43 Featured) -

  • Abbott Laboratories
  • Alere, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Cosmed Srl
  • Philips Healthcare
  • SDI Diagnostics
  • Seegene, Inc.
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Respiratory Diagnostics: Overview & Outlook
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Mounting Burden of Respiratory Diseases: Major Driver
    • Pulmonary Function Test: Major Category
    • Imaging Tests Gain Traction
    • CT Screening for Improved Pulmonary Pathology
    • Bronchoscopy & Laryngoscopy for Evaluating the Airway Directly
    • Rising Cost of Medical Treatment Deters Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Respiratory Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Respiratory Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Respiratory Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Tuberculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Tuberculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Tuberculosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Hospital/Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Hospital/Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Hospital/Clinical Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Physician Offices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Physician Offices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Physician Offices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 28: USA Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 31: USA Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: USA 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 34: Canada Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 37: Canada Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Canada 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 40: Japan Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 43: Japan Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Japan Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Japan 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 46: China Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: China Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: China 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 49: China Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: China Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: China 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 52: Europe Current & Future Analysis for Respiratory Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Respiratory Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Respiratory Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 58: Europe Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Europe Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Europe 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 61: France Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: France 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 64: France Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: France Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: France 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 67: Germany Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 70: Germany Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Germany Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Germany 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 73: Italy Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 76: Italy Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Italy Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Italy 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 79: UK Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: UK 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 82: UK Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: UK Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: UK 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 85: Spain Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Spain Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Spain 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 88: Spain Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Spain Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Spain 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 91: Russia Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Russia Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Russia 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 94: Russia Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Russia Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Russia 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 97: Rest of Europe Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of Europe Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of Europe 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 100: Rest of Europe Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Rest of Europe Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Rest of Europe 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 103: Asia-Pacific Current & Future Analysis for Respiratory Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 104: Asia-Pacific Historic Review for Respiratory Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Asia-Pacific 15-Year Perspective for Respiratory Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 106: Asia-Pacific Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Asia-Pacific Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Asia-Pacific 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 109: Asia-Pacific Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Asia-Pacific Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Asia-Pacific 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 112: Australia Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Australia Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Australia 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 115: Australia Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Australia Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Australia 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 118: India Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: India Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: India 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 121: India Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: India Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: India 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 124: South Korea Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: South Korea Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: South Korea 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 127: South Korea Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: South Korea Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: South Korea 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 130: Rest of Asia-Pacific Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Rest of Asia-Pacific Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Rest of Asia-Pacific 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 133: Rest of Asia-Pacific Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Rest of Asia-Pacific Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Rest of Asia-Pacific 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 136: Latin America Current & Future Analysis for Respiratory Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 137: Latin America Historic Review for Respiratory Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Latin America 15-Year Perspective for Respiratory Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 139: Latin America Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Latin America Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Latin America 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 142: Latin America Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Latin America Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Latin America 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 145: Argentina Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Argentina Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Argentina 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 148: Argentina Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Argentina Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Argentina 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 151: Brazil Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Brazil Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Brazil 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 154: Brazil Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Brazil Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Brazil 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 157: Mexico Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Mexico Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Mexico 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 160: Mexico Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Mexico Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Mexico 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 163: Rest of Latin America Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Rest of Latin America Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Rest of Latin America 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 166: Rest of Latin America Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Rest of Latin America Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Rest of Latin America 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 169: Middle East Current & Future Analysis for Respiratory Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 170: Middle East Historic Review for Respiratory Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Middle East 15-Year Perspective for Respiratory Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 172: Middle East Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Middle East Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Middle East 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 175: Middle East Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Middle East Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Middle East 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 178: Iran Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Iran Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Iran 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 181: Iran Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Iran Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: Iran 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 184: Israel Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Israel Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: Israel 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 187: Israel Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Israel Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: Israel 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 190: Saudi Arabia Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Saudi Arabia Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: Saudi Arabia 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 193: Saudi Arabia Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Saudi Arabia Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: Saudi Arabia 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 196: UAE Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: UAE Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: UAE 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 199: UAE Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: UAE Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: UAE 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 202: Rest of Middle East Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Rest of Middle East Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Rest of Middle East 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 205: Rest of Middle East Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Rest of Middle East Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: Rest of Middle East 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 208: Africa Current & Future Analysis for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Africa Historic Review for Respiratory Diagnostics by Disease - Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: Africa 15-Year Perspective for Respiratory Diagnostics by Disease - Percentage Breakdown of Value Sales for Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease and Other Diseases for the Years 2012, 2020 & 2027
    • TABLE 211: Africa Current & Future Analysis for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Africa Historic Review for Respiratory Diagnostics by End-Use - Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 213: Africa 15-Year Perspective for Respiratory Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End-Uses for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 43